Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older

Collaborative modeling of screening outcomes

Amy Trentham-Dietz, Karla Kerlikowske, Natasha K. Stout, Diana L. Miglioretti, Clyde B. Schechter, Mehmet Ali Ergun, Jeroen J. Van Den Broek, Oguzhan Alagoz, Brian L. Sprague, Nicolien T. Van Ravesteyn, Aimee M. Near, Ronald E. Gangnon, John M. Hampton, Young Chandler, Harry J. De Koning, Jeanne S. Mandelblatt, Anna N A Tosteson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results: Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation: Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion: Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening.

Original languageEnglish (US)
Pages (from-to)700-712
Number of pages13
JournalAnnals of Internal Medicine
Volume165
Issue number10
DOIs
StatePublished - Nov 15 2016

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Quality-Adjusted Life Years
Mammography
Breast Density
Breast
Biopsy
Life Expectancy
Cost-Benefit Analysis
Age Groups
Quality of Life

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older : Collaborative modeling of screening outcomes. / Trentham-Dietz, Amy; Kerlikowske, Karla; Stout, Natasha K.; Miglioretti, Diana L.; Schechter, Clyde B.; Ergun, Mehmet Ali; Van Den Broek, Jeroen J.; Alagoz, Oguzhan; Sprague, Brian L.; Van Ravesteyn, Nicolien T.; Near, Aimee M.; Gangnon, Ronald E.; Hampton, John M.; Chandler, Young; De Koning, Harry J.; Mandelblatt, Jeanne S.; Tosteson, Anna N A.

In: Annals of Internal Medicine, Vol. 165, No. 10, 15.11.2016, p. 700-712.

Research output: Contribution to journalArticle

Trentham-Dietz, A, Kerlikowske, K, Stout, NK, Miglioretti, DL, Schechter, CB, Ergun, MA, Van Den Broek, JJ, Alagoz, O, Sprague, BL, Van Ravesteyn, NT, Near, AM, Gangnon, RE, Hampton, JM, Chandler, Y, De Koning, HJ, Mandelblatt, JS & Tosteson, ANA 2016, 'Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: Collaborative modeling of screening outcomes', Annals of Internal Medicine, vol. 165, no. 10, pp. 700-712. https://doi.org/10.7326/M16-0476
Trentham-Dietz, Amy ; Kerlikowske, Karla ; Stout, Natasha K. ; Miglioretti, Diana L. ; Schechter, Clyde B. ; Ergun, Mehmet Ali ; Van Den Broek, Jeroen J. ; Alagoz, Oguzhan ; Sprague, Brian L. ; Van Ravesteyn, Nicolien T. ; Near, Aimee M. ; Gangnon, Ronald E. ; Hampton, John M. ; Chandler, Young ; De Koning, Harry J. ; Mandelblatt, Jeanne S. ; Tosteson, Anna N A. / Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older : Collaborative modeling of screening outcomes. In: Annals of Internal Medicine. 2016 ; Vol. 165, No. 10. pp. 700-712.
@article{3c5a1820b8a24e8dab54afd7130f9db8,
title = "Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: Collaborative modeling of screening outcomes",
abstract = "Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results: Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation: Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion: Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening.",
author = "Amy Trentham-Dietz and Karla Kerlikowske and Stout, {Natasha K.} and Miglioretti, {Diana L.} and Schechter, {Clyde B.} and Ergun, {Mehmet Ali} and {Van Den Broek}, {Jeroen J.} and Oguzhan Alagoz and Sprague, {Brian L.} and {Van Ravesteyn}, {Nicolien T.} and Near, {Aimee M.} and Gangnon, {Ronald E.} and Hampton, {John M.} and Young Chandler and {De Koning}, {Harry J.} and Mandelblatt, {Jeanne S.} and Tosteson, {Anna N A}",
year = "2016",
month = "11",
day = "15",
doi = "10.7326/M16-0476",
language = "English (US)",
volume = "165",
pages = "700--712",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older

T2 - Collaborative modeling of screening outcomes

AU - Trentham-Dietz, Amy

AU - Kerlikowske, Karla

AU - Stout, Natasha K.

AU - Miglioretti, Diana L.

AU - Schechter, Clyde B.

AU - Ergun, Mehmet Ali

AU - Van Den Broek, Jeroen J.

AU - Alagoz, Oguzhan

AU - Sprague, Brian L.

AU - Van Ravesteyn, Nicolien T.

AU - Near, Aimee M.

AU - Gangnon, Ronald E.

AU - Hampton, John M.

AU - Chandler, Young

AU - De Koning, Harry J.

AU - Mandelblatt, Jeanne S.

AU - Tosteson, Anna N A

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results: Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation: Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion: Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening.

AB - Background: Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective: To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design: Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting: United States. Patients: Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention: Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results: Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation: Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion: Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening.

UR - http://www.scopus.com/inward/record.url?scp=84995899174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995899174&partnerID=8YFLogxK

U2 - 10.7326/M16-0476

DO - 10.7326/M16-0476

M3 - Article

VL - 165

SP - 700

EP - 712

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -